Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Sargramostim

Review the clinical trials studying sargramostim on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-10 of 10

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Status: Active
Location: 662 locations
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)
Status: Active
Location: 147 locations
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage I-III Breast Cancer in Patients with Residual Disease after Chemotherapy and Surgery
Status: Active
Location: 15 locations
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF alone or in Combination with Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
TGFbeta-imprinted Natural Killer Cells in Combination with Irinotecan, Temozolomide, and Dinutuximab for the Treatment of Patients with Relapsed or Refractory Neuroblastoma, Allo-STING Trial
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Status: Active
Location: See ClinicalTrials.gov
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients with Progressing Metastatic Neuroendocrine Carcinomas
Status: Approved
Location: Roswell Park Cancer Institute, Buffalo, New York
A Cancer Vaccine (STEMVAC) in Combination with Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Testing the Safety, Tolerability and Immunological Effects of SurVaxM in Children and Young Adults with Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Status: Temporarily Closed to Accrual
Location: 13 locations